Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [2] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates to provide readily available cell therapy on-demand, more reliably, and at greater scale to a larger patient population [2] Recent Developments - Allogene Therapeutics will participate in a panel discussion on innovations in the allogeneic cell therapy landscape during the Goldman Sachs Cell Therapy Day on October 1, 2024, in New York [1] - The panel discussion is scheduled for 10:00 AM PT / 1:00 PM ET, and a webcast will be available on the company's website, with a replay accessible for approximately 30 days [1]